Investing.comCodex · 实盘不做把握 5/10
北京时间·🕒 发布 20:36:37时区推断·⟳ 抓取 20:37:57·⚡ 决策 07-30 20:40:38 +2m41s·89.1 天前
CEL-SCI的Multikine口腔癌研究论文获Oral Oncology接收但暂未披露新数据
本次新增事实只是论文被同行评议期刊接收，科学结论需待正式发表后披露，不是FDA批准、注册试验读出或商业化里程碑。
📄 原文Investing.com↗ 原文
CEL-SCI study on Multikine in oral cancer accepted for publication
U.S. launches fresh strikes on Iran as fighting intensifies across Middle East VIENNA, Va. - CEL-SCI Corporation (NYSE…
不做 CEL-SCI（CVM.US）
论文接收不是监管批准或新临床读出，核心疗效和注册研究信息已多次公开，且盘前股价反跌；当前不做，等正式发表披露新增数据或监管节点再重判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司已披露FDA允许推进212例确认性注册研究，并披露目标人群5年生存率73%对45%的核心数据，说明本次稿件中的关键数字并非首次出现。
- 公司宣布启动全球确认性注册研究，再次披露212例设计、约97%统计效能和73%对45%的既有疗效口径。
- Investing.com报道称Multikine相关Phase 3 IT-MATTERS论文被Oral Oncology接收，但公司称科学发现需正式发表后再披露。市场反应:CVM盘前最新价1.14美元，较前收1.20美元下跌5.0%。
- 2026-07-30 12:38 UTC市场反应Futu行情非一手行情显示CEL-SCI（CVM.US）并未因该稿件接收消息出现同向买盘，反而盘前下跌。市场反应:CVM.US 1.14美元，-5.0%。
关键理由
- 本次新增事实只是论文被同行评议期刊接收，科学结论需待正式发表后披露，不是FDA批准、注册试验读出或商业化里程碑。
- 文中核心疗效数字5年OS 73%对45%及212例确认性注册研究路径已在2024年FDA沟通、2026年7月注册研究启动公告中反复披露，本次预期差较弱。
- CEL-SCI（CVM.US）仍为无获批收入的临床阶段公司，现价1.14美元、盘前较前收跌5.0%，市场没有把该新闻当作可立即重定价的正向催化。
主要风险
- 若Oral Oncology正式发表时披露新增统计、同行评议细节或监管可采纳性强于既有口径，可能触发新的小盘生物科技交易窗口。
- 公司仍需完成全球212例确认性注册研究且Multikine未获任何监管机构批准销售，融资摊薄和试验复现风险较高。
反向证据
- 做多前查反向 · 来源 kb_search · 影响 none
内部KB未命中当前论文接收事件的有效付费研究覆盖，未提供足以把期刊接收升级为交易利好的新增量级证据。
检索:CEL-SCI Multikine low PD-L1 oral cancer Phase 3 publication accepted Oral Oncology - 做多前查反向 · 来源 web · 日期 2024-05-08 · 影响 weakens
核心疗效数据和212例确认性研究路径已由公司早前官方公告披露，削弱本次新闻的新鲜度。
检索:CEL-SCI Multikine 73% 45% 212 patient confirmatory study old disclosure 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-05-13 · 影响 weakens
公司5月完成720万美元公开发行且用途包括Multikine开发和营运资金，临床阶段融资摊薄风险未消除。
检索:CEL-SCI public offering 2026 Multikine development funding dilution 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,979 字
U.S. launches fresh strikes on Iran as fighting intensifies across Middle East
VIENNA, Va. - CEL-SCI Corporation (NYSE American:CVM) announced today that a manuscript from its Phase 3 IT-MATTERS clinical trial has been accepted for publication in Oral Oncology, a peer-reviewed journal focused on head and neck cancer research.
The manuscript, authored by Eyal Talor, the company’s Chief Scientific Officer, examines Multikine’s efficacy in oral cancer patients with low tumor PD-L1 expression. The company stated it will disclose the scientific findings after publication in accordance with the journal’s policies.
According to the press release, the Phase 3 study evaluated Multikine in newly diagnosed, treatment-naive, resectable, locally advanced head and neck cancer patients. In a subset of patients with low tumor PD-L1 expression and no lymph node involvement who received Multikine before standard care, the five-year overall survival rate was 73% compared to 45% in patients receiving standard care alone.
Multikine is being developed for patients with low PD-L1 tumor expression, a population the company describes as underserved. This differs from currently available immune checkpoint inhibitor therapies that primarily target patients with higher PD-L1 expression.
CEL-SCI stated it is preparing to begin enrollment in a global 212-patient Confirmatory Registration Study designed to verify the overall survival benefit observed in the Phase 3 trial. The registration study will enroll patients at clinical centers across the United States, Europe and Asia.
Multikine has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck. The investigational therapy has been administered to over 740 patients but has not been approved for sale by the FDA or any other regulatory agency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
VIENNA, Va. - CEL-SCI Corporation (NYSE American:CVM) announced today that a manuscript from its Phase 3 IT-MATTERS clinical trial has been accepted for publication in Oral Oncology, a peer-reviewed journal focused on head and neck cancer research.
The manuscript, authored by Eyal Talor, the company’s Chief Scientific Officer, examines Multikine’s efficacy in oral cancer patients with low tumor PD-L1 expression. The company stated it will disclose the scientific findings after publication in accordance with the journal’s policies.
According to the press release, the Phase 3 study evaluated Multikine in newly diagnosed, treatment-naive, resectable, locally advanced head and neck cancer patients. In a subset of patients with low tumor PD-L1 expression and no lymph node involvement who received Multikine before standard care, the five-year overall survival rate was 73% compared to 45% in patients receiving standard care alone.
Multikine is being developed for patients with low PD-L1 tumor expression, a population the company describes as underserved. This differs from currently available immune checkpoint inhibitor therapies that primarily target patients with higher PD-L1 expression.
CEL-SCI stated it is preparing to begin enrollment in a global 212-patient Confirmatory Registration Study designed to verify the overall survival benefit observed in the Phase 3 trial. The registration study will enroll patients at clinical centers across the United States, Europe and Asia.
Multikine has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma of the head and neck. The investigational therapy has been administered to over 740 patients but has not been approved for sale by the FDA or any other regulatory agency.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。